The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations.

Glaucoma treatment systems are disclosed. In various example, the glaucoma treatment systems include a body and a fluid conduit configured to facilitate an evacuation of fluid, such as aqueous humor, from a fluid-filled body cavity, such as an anterior chamber of an eye. In some examples, the fluid conduit is soft and compliant, and the glaucoma treatment system includes one or more stiffening members coupled with the fluid conduit to temporarily stiffen the fluid conduit and help aid in the delivery of the glaucoma treatment device. In some examples, the stiffening members are removable from the fluid conduit after the glaucoma treatment system has been implanted.

The invention relates to an assembly (10) comprising an OCT device (20) for scanning an object region volume (22) arranged in an object region (18) using an OCT scanning beam (21), an object (24) with a section, which can be arranged in the object region (18) and which can be located in the object region volume (22) by means of the OCT device (20), in the object region volume (22), and a calculating unit (60) which is connected to the OCT device (20) and contains a computer program for ascertaining a 3D reconstruction of the object region volume (22) and for ascertaining the position of the section of the object (24) in the object region volume (22) by processing OCT scanning information obtained by scanning the object region volume (22) using the OCT device (20). According to the invention, the computer program has a calculation routine for ascertaining a target area (90) in the 3D reconstruction of the object region volume (22), said calculation routine determining a reference variable for the object (24) relative to the target area (90). The object (24) is designed as a surgical instrument which has a capillary with an opening for discharging a medium. The calculation routine of the computer program is used to ascertain an actual value of the volume of the medium discharged through the opening of the capillary in the target area by comparing data of the target area in the 3D reconstruction of the object region volume (22) and/or by comparing scanning information of the target area obtained by scanning the object region volume (22) using the OCT device (20) prior to and while discharging the medium. The invention also relates to a computer program and to a method for determining the volume of a medium discharged in an object region (18) through an opening by means of a surgical instrument with a capillary.

Embodiments disclosed herein relate to systems and methods for securing a drug delivery component to an intraocular lens (IOL) assembly. The systems generally include a support base and a plunger. The support base includes a first portion configured to accommodate a drug delivery component; and a second portion configured to act as a plunger guide. The plunger can be inserted into the plunger guide such that the plunger is positioned to interface with a drug delivery component and an IOL assembly during use. The plunger includes an elongated body and a tip, wherein the tip can include a ramp configured to interface with a fixation loop of a drug delivery component during use and a compartment configured to interface with a haptic of an IOL assembly during use.

Embodiments disclosed herein generally relate to a stabilized intraocular drug delivery system for implantation into an eye of a subject. The system can include an intraocular lens (IOL) assembly and a drug delivery component. The IOL assembly can include a lens and a haptic. The haptic can include an outer end, an inner end opposite the outer end, a retention tab at the inner end, and a connection tab positioned between the outer end and the inner end and adjoining the lens. The drug delivery component can include at least one therapeutic agent and a fixation portion having an opening to receive the haptic and secure the drug delivery component to the IOL assembly. The fixation portion of the drug delivery component can be secured to the connection tab of the haptic such that the retention tab inhibits movement of the drug delivery component relative to the IOL assembly.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A punctum plug or lacrimal insert is constructed of a monolithic material, such that the punctum plug is configured to turn approximately 90 degrees upon insertion into a canaliculus of an eye. The punctum plug or lacrimal insert may include high-molecular-weight polysaccharide and added plasticizers.

Devices and methods for inserting a pre-loaded intracanalicular plug for the treatment of dry eyes. In one embodiment, an intracanalicular plug inserter device includes: (a) an elongate body having a longitudinal axis, the body having: an inserter end, wherein the inserter end has an opening therein; and a distal end, wherein the distal end is longitudinally opposing the inserter end; and (b) a plug ejector, wherein the plug injector comprises: a slider; and a rod coupled to a first end of the slider, wherein the plug ejector is configured to be moveable between a first position adjacent an opening in the inserter end and a second position that is further from the opening. The plug is mounted within the body and abuts first end of the rod adjacent the opening in the inserter end.

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).